MedTrace Logo

Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

NCT04457726 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-07-07

No results posted yet for this study

Summary

The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe SARS-CoV-2 infections.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 Specific T Cells

Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.

Sponsors & Collaborators

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • National University Hospital, Singapore

    collaborator OTHER

  • Singapore General Hospital

    collaborator OTHER

  • Sengkang General Hospital

    collaborator OTHER

  • Changi General Hospital

    collaborator OTHER

  • KK Women's and Children's Hospital

    lead OTHER_GOV

Principal Investigators

  • Wing Hang Leung · KK Hospital, SingHealth Duke NUS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-03-31
Completion
2022-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04457726 on ClinicalTrials.gov